FINDEX Inc. AI Stock Analysis
Want to see JP:3649 full AI Analyst Report?
FINDEX Inc. (3649) AI Stock Analysis
FINDEX Inc.
(TSE/TYO:3649)
The company's exceptional financial strength, characterized by a debt-free balance sheet, high profitability, and strong cash flows, is the primary driver of the score. This is partially offset by a weak technical outlook, with the stock trading below key moving averages and exhibiting negative momentum. The moderate valuation and attractive 3.25% dividend yield provide a balanced support to the overall assessment.
FINDEX Inc. (3649) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 19.44B
- Dividend Yield
- 3.34%
- Average Volume (3M)
- 57.59K
- Price to Earnings (P/E)
- 18.8
- Beta (1Y)
- 0.46
- Revenue Growth
- 2.22%
- EPS Growth
- -8.47%
- Country
- Japan
- Employees
- 325
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
FINDEX Inc. Business Overview & Revenue Model
Company Description
FINDEX Inc., a company established in Tokyo in 1985, focuses on the creation, production, and distribution of medical technology systems across Japan. Their portfolio features Claio, a comprehensive medical imaging database management system utilized...
FINDEX Inc. Financial Statement Overview
Summary
Financial health is excellent. The balance sheet is pristine with zero debt and a strong equity base, driving an ROE above 20%. Profitability is high with a 65.2% gross margin and 20.6% net margin, supported by robust cash flow generation where operating cash flow covers net income by 1.3x. The only minor watch item is a deceleration in revenue growth to 6.0%.
Income Statement
90Very PositiveBalance Sheet
95Very PositiveCash Flow
90Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.13B | 6.11B | 5.84B | 5.19B | 4.54B | 4.97B |
| Gross Profit | 4.02B | 3.98B | 3.55B | 3.33B | 2.72B | 2.56B |
| EBITDA | 2.02B | 2.09B | 1.83B | 1.78B | 1.32B | 1.25B |
| Net Income | 1.13B | 1.26B | 1.16B | 1.06B | 722.78M | 636.03M |
Balance Sheet | ||||||
| Total Assets | 6.92B | 6.81B | 6.69B | 5.94B | 4.98B | 4.56B |
| Cash, Cash Equivalents and Short-Term Investments | 2.47B | 1.68B | 1.73B | 2.69B | 2.41B | 2.17B |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 20.00M |
| Total Liabilities | 1.24B | 1.34B | 1.08B | 1.09B | 939.06M | 1.04B |
| Stockholders Equity | 5.65B | 5.44B | 5.60B | 4.84B | 4.04B | 3.51B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 1.62B | 1.87B | 559.87M | 621.08M | 681.02M |
| Operating Cash Flow | 0 | 1.65B | 1.90B | 842.84M | 693.85M | 750.35M |
| Investing Cash Flow | 0 | -297.86M | -2.43B | -296.94M | -230.16M | -490.37M |
| Financing Cash Flow | 0 | -1.41B | -412.54M | -270.49M | -142.02M | -186.34M |
FINDEX Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3649, the sentiment is Negative. The current price of 800.00 is below the 20-day moving average (MA) of 843.85, below the 50-day MA of 859.22, and below the 200-day MA of 835.00, indicating a bearish trend. The MACD of -13.39 indicates Positive momentum. The RSI at 38.09 is Neutral, neither overbought nor oversold. The STOCH value of 29.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3649.
FINDEX Inc. Peers Comparison
Overall Rating
JP:393982Outperform
JP:364975Outperform
JP:241372Outperform
JP:448372Outperform
JP:448054Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 82Outperform | JPY 23.85B | 16.25 | ― | 1.89% | 12.07% | 30.31% | |
| 75Outperform | JPY 20.72B | 18.75 | ― | 3.34% | 2.22% | -8.47% | |
| 72Outperform | JPY 1.18T | 25.08 | 11.33% | 1.26% | 9.48% | 2.08% | |
| 72Outperform | JPY 232.67B | 31.20 | ― | 0.51% | 20.50% | 19.27% | |
| 54Neutral | JPY 56.52B | 32.99 | 11.30% | ― | 21.01% | 10.15% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:3649 | FINDEX Inc. | 800.00 | -84.41 | -9.54% | |
| JP:2413 | M3 | 1681.00 | -918.33 | -35.33% | |
| JP:4480 | Medley, Inc. | 1780.00 | -870.00 | -32.83% | |
| JP:3939 | Kanamic Network Co., LTD. | 489.00 | -28.32 | -5.47% | |
| JP:4483 | JMDC Inc. | 3440.00 | -759.57 | -18.09% |
FINDEX Inc. Corporate Events
FINDEX Issues H1 FY2026 Results Presentation With Strong Legal Disclaimers
FINDEX Inc. has released its H1 FY2026 financial results presentation with extensive disclaimers that the information is provided solely for informational purposes. The company stresses that the materials, including business plans and target figures,...
FINDEX Posts Softer H1 Profits but Lifts Dividend and Confirms 2026 Outlook
FINDEX Inc. reported modest revenue growth for the first half of 2026, with net sales edging up 0.6% year-on-year to ¥3.15 billion, while operating profit fell 7.0% and profit attributable to owners of parent dropped 18.2%, pressuring earnings per sh...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026
